THIS INFORMATION IS INTENDED FOR US HEALTHCARE PROFESSIONALS
ABOUT CUMBERLAND  |  IMPORTANT SAFETY INFORMATION  |  FULL PRESCRIBING INFORMATION  |  NEWS
logo
register

Increased serum sodium maintained (30 days)

The effect of Vaprisol on serum sodium was demonstrated in an open-label study of 251 patients with euvolemic or hypervolemic hyponatremia, the primary endpoint of which was baseline adjusted serum sodium AUC over duration of treatment (mEq·hr/L). Patients were treated for 4 days with Vaprisol 20 mg/day IV or 40 mg/day IV (n=37, n=214, respectively) following a 20-mg loading dose via 30-minute IV infusion. The mean baseline serum sodium concentrations in patients treated with Vaprisol 20 mg/day IV or 40 mg/day IV were 122.5 mEq/L and 123.8 mEq/L, respectively.1,2

  • Mean changes in serum sodium concentration from baseline to end of treatment (day 4) in patients receiving Vaprisol 20 mg/day or 40 mg/day IV were 9.4 mEq/L and 8.8 mEq/L, respectively1
  • Increased serum sodium concentration was maintained for up to 30 days post-treatment1*

*The effect of Vaprisol on maintenance of serum sodium concentration is not known.



REFERENCES: 1. Vaprisol Prescribing Information. Cumberland Pharmaceuticals Inc. 2. Data on file. Cumberland Pharmaceuticals.